Arylalkylamine compounds, methods for producing the same, and their use

Arylalkylamine compounds targeting CaSR provide a safer and more effective treatment for SHPT by inhibiting PTH secretion and stabilizing calcium and phosphorus levels, addressing the limitations of current treatments.

JP2026539115AActive Publication Date: 2026-11-19런허 이캉 그룹 컴퍼니 리미티드
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026529966
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-18
Filing Date
2025-02-28
Publication Date
2026-11-19
Estimated Expiration
2045-02-28

AI Technical Summary

Technical Problem

Current treatments for secondary hyperparathyroidism (SHPT) associated with chronic kidney disease are costly, have a narrow therapeutic range, incomplete treatment, high relapse rates, and can develop resistance, with calcium mimetic drugs like evocalcet posing adverse events.

Method used

Development of arylalkylamine compounds with high activity and safety, specifically targeting calcium-sensing receptors (CaSR) to inhibit parathyroid hormone synthesis and secretion, stabilizing blood calcium and phosphorus levels.

Benefits of technology

The arylalkylamine compounds exhibit excellent CaSR activating activity, high bioavailability, metabolic stability, and safety, effectively treating SHPT with reduced adverse effects compared to existing drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026539115000001_ABST
    Figure 2026539115000001_ABST
Patent Text Reader

Abstract

The present invention relates to arylalkylamine compounds, methods for producing the same, and uses thereof. The arylalkylamine compounds of the present invention have the following structure of formula (I), R 1 , R 2 , R 3 , R 4 , R 5 This is defined in the specification. The compounds of the present invention have excellent CaSR activating activity, high bioavailability, high metabolic stability in vivo, and high safety. [Formula 1] TIFF2026539115000026.tif49170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention belongs to the pharmaceutical field and, more specifically, relates to arylalkylamine compounds, methods for producing the same, and the use of allosteric effects to activate calcium-sensing receptors (CaSR). [Background technology]

[0002] Chronic kidney disease can cause secondary hyperparathyroidism (SHPT). Currently, there are various treatment methods for SHPT both domestically and internationally. However, these methods have drawbacks such as high cost, narrow therapeutic range, incomplete treatment, a high relapse rate, and the development of resistance. Calcium mimetic drugs have greater clinical advantages because they act directly on CaSR and can effectively control the synthesis and secretion of parathyroid hormone (PTH).

[0003] Tanabe Mitsubishi Pharma Corporation has developed the calcium mimetic drug evocalcet (WO2005115975). It was first approved for sale in Japan in March 2018. According to the review report for evocalcet, adverse events mainly include hypocalcemia, vomiting, nausea, chills, QT prolongation, mood disorders, arrhythmias, hypotension, and seizures (Orkedia Tablets 1 mg and 2 mg Review Report, March 2018). [ka]

[0004] Therefore, developing calcium mimetic drugs with higher activity and safety, particularly arylalkylamine compounds, and using them to treat SHPT in patients, has extremely great clinical and social value. [Overview of the project] [Problems that the invention aims to solve]

[0005] The present invention has been made to solve the drawbacks of the prior art, and an object thereof is to provide an arylalkylamine compound having higher activity and safety. The compound of the present invention has characteristics such as excellent CaSR activating activity, high bioavailability, high in vivo metabolic stability, and high safety. The present invention is realized by the following technical embodiments. [MEANS FOR SOLVING THE PROBLEMS]

[0006] In one aspect, the present invention provides a compound having a structure represented by the following formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, [Chemical Formula] Here, R 1 , R 2 , R 3 , R 4 , R 5 are each independently a hydrogen atom; C 2~6 carboxy group (-(CH2) n COOH, n is an integer of 1 to 5); a halogen, a cyano group, a nitro group, oxygen, C 1~6 carboxy group (-(CH2) n COOH, n is an integer of 0 to 5), an amine group, C 3~6 cycloalkyl group, aryl C 1~6 alkoxy group (e.g., benzyloxy group), hydroxy group, C 1~6 alkoxy group, halo C 1~6 alkyl group and halo C 1~6 alkoxy group, which may be substituted with a substituent selected from C 1~7 alkoxy group (which may be a cyclic alkoxy group or a chain alkoxy group); a halogen; C 1~6 alkyl group; halo C 1~6 alkyl group, provided that 1) R 1 , R 2 , R 3 , R 4 , R 5 are not H at the same time, and 2) when the substituent is a C 2~6 carboxy group, the substitution site is R2 ~R 4 And R 1 ~R 5 At least two of them are not H.

[0007] Preferably, R 1 , R 5 H, halogens (e.g., F, Cl), C 1~6 Alkyl groups (e.g., methyl group, ethyl group), C 1~6 It is selected from alkoxy groups (e.g., methoxy group, ethoxy group).

[0008] Preferably, R 2 ~R 4 At least one of them is either an unsubstituted or substituted C 2~6 It is a carboxyl group, preferably a carboxymethyl group (i.e., -CH2COOH), and R 1 ~R 5 At least two of these are not hydrogen atoms. That is, at least one of the para or meta positions is a carboxymethyl group, and at least one other position is substituted.

[0009] Preferably, R 2 ~R 4 At least one of them is an unsubstituted or substituted carboxymethyl group, and R 1 ~R 5 At least two of these are not hydrogen atoms. That is, at least one of the para or meta positions is a carboxymethyl group, and at least one other position is substituted.

[0010] Preferably, R 1 , R 2 , R 4 , R 5 These are H, halogens (e.g., F, Cl), and C, respectively, independently. 1~6 Alkyl groups (e.g., methyl group, ethyl group), C 1~6 Selected from alkoxy groups (e.g., methoxy group, ethoxy group, etc.), C 1~6 The alkoxy group is a hydroxyl group, C 1~6 Substituting with a substituent selected from the alkoxy group, and R1 , R 2 , R 4 , R 5 It is not possible for both to be H at the same time, R 3 is C 2~6 It is a carboxyl group.

[0011] Preferably, R 1 , R 2 , R 4 , R 5 These are H, halogens (e.g., F, Cl), and C, respectively, independently. 1~6 Alkyl groups (e.g., methyl group, ethyl group), C 1~6 Selected from alkoxy groups (e.g., methoxy group, ethoxy group, etc.), C 1~6 The alkoxy group is a hydroxyl group, C 1~6 Substituting with a substituent selected from the alkoxy group, and R 1 , R 2 , R 4 , R 5 It is not possible for both to be H at the same time, R 3 It is a carboxymethyl group.

[0012] In one specific embodiment, the compound of formula (I) is selected from the following: [ka]

[0013] The compound of general formula (I) of the present invention may be in free form or in the form of a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable inorganic salts include hydrochloride, sulfate, phosphate, or hydrobromide. Examples of pharmaceutically acceptable organic salts include acetate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, or maleate. Furthermore, if the compound has an acidic group such as a carboxyl group, it can form a salt of a metal ion, such as an alkali metal salt or alkaline earth metal salt such as a sodium salt, potassium salt, or calcium salt.

[0014] In another embodiment, the present invention includes the step of reacting a compound of formula A with a compound of formula (II) to produce a compound of formula (I), [ka] Here, X represents a leaving group, such as a halogen, a hydroxyl group, or a lower alkylsulfonyloxy group (for example, C 1~6 The present invention provides a method for producing the compound of formula (I), which is selected from alkylsulfonyloxy groups, sulfonyloxy groups, etc., and preferably Br, Cl, or trifluoromethanesulfonyloxy groups.

[0015] In a further embodiment, the present invention provides a pharmaceutical composition comprising the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.

[0016] Specifically, when used as a pharmaceutical active ingredient, the compound of formula (I) of the present invention or a pharmaceutically acceptable salt thereof can be used with an inert carrier suitable for various administration methods and can be formulated as a conventional pharmaceutical preparation, such as tablets, granules, capsules, powders, solutions, suspensions, emulsions, and injections. When used as a solid preparation, the inert carrier includes a binder (such as gum arabic, gelatin, sorbitol, or polyvinylpyrrolidone), excipients (such as lactose, galactose, corn starch, or sorbitol), lubricants (such as magnesium stearate, talc, or polyethylene glycol), and disintegrants (such as potato starch). When used as an injection, it can be prepared with distilled water for injection, physiological saline, or glucose aqueous solution.

[0017] The pharmaceutically acceptable compound of formula (I) or a pharmaceutically acceptable salt thereof of the present invention may be administered by oral, intravenous, intramuscular, subcutaneous, or transdermal absorption, and the dose and volume can be determined according to factors such as the properties of the drug, the route of administration, the patient's age, weight, or disease state.

[0018] The present invention provides a pharmaceutical composition comprising the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, or the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient. It is used to prevent and treat CaSR-related diseases by activating CaSR and producing various pharmacological effects. For example, by activating CaSR, it inhibits PTH production and regulates blood calcium and phosphorus levels, and is used in primary hyperparathyroidism, secondary hyperparathyroidism, tertiary hyperparathyroidism, chronic renal failure (with or without dialysis), chronic kidney disease (with or without dialysis), parathyroid adenoma, parathyroid hyperplasia, parathyroid cancer, vascular calcification and valve calcification, calcium homeostasis abnormalities (e.g., hypercalcemia), phosphorus homeostasis abnormalities (e.g., hypophosphatemia), bone-related diseases or complications caused by hyperparathyroidism and caused by chronic kidney disease or parathyroid cancer, post-renal osteopenia, cystic fibrous osteitis, asthenic osteodystrophy, renal osteodystrophy, cardiovascular complications caused by hyperparathyroidism or chronic kidney disease, Ca 2+ It is used to treat certain malignant tumors with abnormally high levels of [unclear].

[0019] Unless otherwise specified, the following terms used in the specification and claims have the meanings set forth below.

[0020] The present invention encompasses all stereoisomers of the aforementioned compounds. Unless otherwise specifically limited, the present invention is intended to encompass all such isomers of these compounds. The chiral centers in the compounds of the present invention can each independently have either an (R) configuration or an (S) configuration. When a bond connected to a chiral carbon is represented by a straight line in the structural formula of the present invention, it should be understood that the (R) and (S) configurations of the chiral carbon, as well as the two enantiomers and mixtures thereof, are all included in that formula. When describing a specific configuration, enantiomer (R) or (S) is indicated. Similarly, when a compound name is given without the name of the chiral carbon, it should be understood that the (R) and (S) configurations of the chiral carbon, as well as the single enantiomer and mixtures thereof, are all included in that name. Examples of obtaining these stereoisomers or mixtures may identify the production of a specific stereoisomer or mixture thereof, but this does not in any way limit the scope of all stereoisomers and mixtures thereof.

[0021] The term "carboxyl group" refers to a fundamental functional group in organic chemistry consisting of one carbon atom, two oxygen atoms, and one hydrogen atom, with the chemical formula -COOH. 1~6 Carboxy group, C 2~6 A carboxyl group is a lower alkyl group containing a carboxyl group. 1~6 The carboxyl group may also be a formic acid group (e.g., -COOH), a carboxymethyl group, a propionic acid group (-(CH2)2COOH), a butyric acid group (-(CH2)3COOH), a valeric acid group (-(CH2)4COOH), or a hexanoic acid group (-(CH2)5COOH). 2~6 The carboxyl group may be a carboxymethyl group, a propionic acid group, a butyric acid group, a valeric acid group, or a hexanoic acid group. [Effects of the Invention]

[0022] The compound of formula (I) of the present invention or a pharmaceutically acceptable salt thereof can be used as an active ingredient to prevent or treat hyperparathyroidism by activating CaSR on parathyroid cells through an allosteric effect, thereby inhibiting the synthesis and secretion of parathyroid hormone, reducing the level of parathyroid hormone in the blood, and further stabilizing the concentrations of blood calcium and blood phosphorus. It exhibits excellent effects in activating CaSR through an allosteric effect and reducing PTH in the body. Experiments on the allosteric activation effect of CaSR, SD rat adenine models, and SD rat 5 / 6 nephrectomy models have confirmed that the compound has an allosteric activation effect on CaSR and an effect of reducing PTH in the body of model rats.

[0023] The compound of formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, not only possesses excellent activity as an active ingredient but also exhibits a certain degree of in vivo stability. In this invention, incubation experiments in rat liver microsomes have demonstrated that the compound indeed possesses metabolic stability. The compound of formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, not only has excellent CaSR activating effects as an active ingredient but also possesses high safety. Compared to the prior art, this invention has not only excellent activity and good safety but also high in vivo metabolic stability and high relative bioavailability in vivo. [Modes for carrying out the invention]

[0024] The present disclosure will be further illustrated below with reference to examples, which are not intended to limit the scope of the present disclosure.

[0025] In this disclosure, known starting materials may be synthesized using or in accordance with known methods in the art, or they may be purchased from chemical manufacturers such as Anneji Pharmaceutical Chemical Co., Ltd., J & K Scientific Ltd., Macklin Biochemical Co., Ltd., Aladdin Biochemical Technology Co., Ltd., and Bide Pharmatech Co., Ltd.

[0026] In the examples, unless otherwise specified, "solution" refers to an aqueous solution, "room temperature" refers to 20-30°C, and "inert gas" refers to argon or nitrogen. The developing solvents used for monitoring the reaction by thin-layer chromatography (TLC) and for purification by column chromatography are dichloromethane / methanol systems, n-hexane / ethyl acetate systems, petroleum ether / ethyl acetate systems, petroleum ether / ethyl acetate / methanol systems, etc. The ratio of the components of the system can be adjusted according to the polarity of the compound, or by adding a small amount of basic or acidic reagent such as triethylamine or acetic acid.

[0027] Unless otherwise specified in the examples, the model numbers of the mass spectrometry (MS), nuclear magnetic resonance (NMR), and high-performance liquid chromatography (HPLC) instruments used to confirm the structure are Agilent InfinityLab LC / MSD iQ G6160A, Bruker AVANCE 400 or Bruker AVANCE NEO 600, and Shimadzu LC-2010AHT, respectively. The solvents used for NMR measurements are deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), or heavy water (D2O), and the internal standard is tetramethylsilane (TMS).

[0028] Example 1: Synthesis of (3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}pyrrolidine dihydrochloride (A) The synthesis route is as follows: [ka] Step 1: 2-Nitrobenzenesulfonic acid-(3R)-1-{[(2-methylpropa-2-yl)oxy]carbonyl}pyrrolidine-3-yl ester (A-2) Compound A-1 (25.00 g, 0.13 mol), triethylamine (17.57 g, 0.17 mol), trimethylamine hydrochloride (2.55 g, 0.03 mol), and 125 mL of dichloromethane were added to a 500 mL three-necked flask and stirred. The mixture was cooled to 0-10°C, and a solution of 2-nitrobenzenesulfonyl chloride (32.55 g, 0.15 mol) in dichloromethane (125 mL) was added dropwise. Once the reaction was complete, 150 mL of purified water was added, and the pH was adjusted to 2.0-4.0 with 6N hydrochloric acid. The mixture was allowed to stand until stratification was clearly observed, and phase separation was performed. The organic phase was retained, and the aqueous phase was extracted once with 50 mL of dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure until a constant weight was obtained to obtain compound A-2 (47.40 g, yield 95%). LCMS(ESI)m / z:373.1[M+H] + .

[0029] Step 2: (3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}pyrrolidine-1-formate-2-methylpropa-2-yl ester (A-3) Compound A-2 (45.00 g, 0.12 mol), (1R)-1-(naphthalene-1-yl)ethane-1-amine (17.60 g, 0.10 mol), potassium phosphate (21.23 g, 0.10 mol), and 150 mL of acetonitrile were added to a 100 mL three-necked flask. The mixture was heated to 75 °C and reacted with stirring for 24 hours. After cooling to room temperature, the mixture was filtered by suction, the filter cake was washed with 60 mL of acetonitrile, and the mixture was concentrated under reduced pressure until no more solvent was distilled. 90 mL of ethyl acetate and 90 mL of saturated saline solution were added and the mixture was stirred for 30 minutes. The mixture was allowed to stand until clear stratification occurred, and phase separation was performed. The organic phase was retained, and the aqueous phase was extracted once with 45 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure until constant weight was obtained to obtain compound A-3 (32.62 g, yield 96%). LCMS(ESI)m / z:341.2[M+H] + .

[0030] Step 3: (3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}pyrrolidine dihydrochloride (A) Compound A-3 (30.00 g, 0.09 mol) and 150 mL of ethyl acetate were added to a 500 mL three-necked flask and stirred. The mixture was cooled to 0-10°C, and 22.5 mL of concentrated hydrochloric acid was added dropwise. Once complete, the mixture was kept warm and stirred for 30 minutes, then heated to 55°C and reacted for 2.0 hours. The mixture was cooled to room temperature, filtered, and the filter cake was washed off with 50 mL of ethyl acetate. The mixture was air-dried at 45°C until constant weight was reached to obtain compound A (19.87 g, 92% yield). LC-MS (ESI) m / z: 241.2 [M+H] + . 1 H NMR(400MHz,MeOH-d4)δ 8.29(d,J=8.8Hz,1H),8.04-7.97(m,2H),7.94(d,J=7.2Hz,1H),7.72-7.58(m,3H),5.60-5.51(m,1H),3.98-3.87(m,1H) ),3.65-3.54(m,1H),3.51-3.38(m,2H),3.29-3.20(m,1H),2.55-2.44(m,1H),2.43-2.32(m,1H),1.89(d,J=6.8Hz,3H).

[0031] Example 2: Synthesis of {2-fluoro-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}acetic acid (1) The synthesis route is as follows: [ka] Step 1: (4-bromo-2-fluorophenyl)ethyl acetate (1-1) Compound B (2.00 g, 8.58 mmol) and 60 mL of ethanol were added to a 250 mL necked flask and stirred. The mixture was cooled to 0°C, 1 mL of concentrated sulfuric acid was added dropwise, and the mixture was heated and refluxed for 3.0 hours. The mixture was cooled to room temperature and concentrated under reduced pressure until no more solvent was distilled. 50 mL of ethyl acetate and 50 mL of purified water were added and stirred. Saturated sodium carbonate solution was added dropwise to adjust the pH to 8.0. The mixture was allowed to stand until clear stratification occurred, and phase separation was performed. The organic phase was retained, and the aqueous phase was extracted once with 50 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure until constant weight was obtained to obtain compound 1-1 (2.00 g, yield 89%). LCMS(ESI) m / z: 261.0[M+H] + .

[0032] Step 2: {2-fluoro-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}ethyl acetate (1-2) In a 250 mL necked flask, add free compound A (1.00 g, 4.16 mmol), compound 1-1 (1.31 g, 4.99 mmol), Pd(OAc)2 (50 mg, 0.20 mmol), X-Phos (100 mg, 0.20 mmol), Cs2CO3 (4.10 g, 12.48 mmol), and 50 mL of toluene. The flask is purged with nitrogen three times, heated to 100 °C, and stirred for 12.0 hours. The mixture is then cooled to room temperature and added to 30 mL of saturated saline solution. The mixture was added and stirred, then allowed to stand until clear stratification occurred. Phase separation was performed, retaining the organic phase. The aqueous phase was extracted once with 20 mL of ethyl acetate, and the organic phases were combined. The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure until no more solvent distilled from the filtrate. The residue was purified by chromatography (200-300 mesh silica gel, petroleum ether:ethyl acetate = 80:20 → 50:50), concentrated under reduced pressure, and compound 1-2 (0.70 g, yield 40%) was obtained. LCMS(ESI) m / z: 421.2[M+H] + .

[0033] Step 3: {2-fluoro-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}acetic acid (1) Compounds 1-2 (0.60 g, 1.43 mmol), sodium hydroxide (572 mg, 14.3 mmol), 10 mL of purified water, and 10 mL of ethanol were added to a 100 mL necked flask. The mixture was reacted at 60°C with stirring for 3.0 hours, cooled to room temperature, and the pH was adjusted with 1 N hydrochloric acid until a solid precipitate clearly formed. The mixture was filtered, the filter cake was washed with 10 mL of purified water, and the mixture was air-dried at 45°C until constant weight was achieved to obtain compound 1 (0.30 g, yield 53%). LC-MS (ESI) m / z: 393.3 [M+H] + . 1H NMR(600MHz,DMSO-d6)δ 8.34(d,J=8.4Hz,1H),7.96(d,J=7.9Hz,1H),7.87(d,J=8.6Hz,2H),7.56(dd,J=14.2,5.9Hz,3H),7.05(t,J=8.6Hz,1H), 6.24(d,J=8.9Hz,2H),4.96(s,1H),3.43(s,3H),3.36(q,J=7.7Hz,2H),3.13(q,J=7.8Hz,2H),2.07(m,2H),1.52(s,3H).

[0034] Example 3: Synthesis of {3-fluoro-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}acetic acid (2) The synthesis route is as follows: [ka] Step 1: (4-bromo-3-fluorophenyl)ethyl acetate (2-1) Compound C (2.00 g, 8.58 mmol) and 60 mL of ethanol were added to a 250 mL necked flask and stirred. The mixture was cooled to 0°C, and 1 mL of concentrated sulfuric acid was added dropwise. The synthesis and workup procedures were the same as for Compound 1-1, yielding Compound 2-1 (1.80 g, 81% yield). LC-MS (ESI) m / z: 261.0 [M+H] + .

[0035] Step 2: {3-fluoro-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}ethyl acetate (2-2) In a 250 mL necked flask, free compound A (1.00 g, 4.16 mmol), compound 2-1 (1.31 g, 4.99 mmol), Pd(OAc)2 (50 mg, 0.20 mmol), X-Phos (100 mg, 0.20 mmol), Cs2CO3 (4.10 g, 12.48 mmol), and 50 mL of toluene were added. The synthesis and workup procedures were carried out according to those for compound 1-2, yielding compound 2-2 (0.89 g, 51% yield). LC-MS (ESI) m / z: 421.2 [M+H] + .

[0036] Step 3: {3-fluoro-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}acetic acid (2) Compound 2-2 (0.80 g, 1.90 mmol), sodium hydroxide (760 mg, 19.0 mmol), 10 mL of purified water, and 10 mL of ethanol were added to a 100 mL necked flask. The synthesis and workup procedures were carried out according to those for Compound 1, and Compound 2 (0.39 g, 52% yield) was obtained. LC-MS (ESI) m / z: 393.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.33-8.26(m,1H),7.93(dd,J=7.0,2.3Hz,1H),7.79(d,J=8.1Hz,1H),7.72(d,J=7.2Hz,1H),7.51( dtd,J=10.2,7.2,4.8Hz,3H),6.91(dd,J=14.9,2.0Hz,1H),6.85(dd,J=8.2,2.0Hz,1H),6.56(t,J= 9.0Hz,1H),4.72(q,J=6.6Hz,1H),3.42-3.28(m,4H),3.19(p,J=6.9,5.9Hz,2H),3.09(ddd,J=8.9, 5.7,2.7Hz,1H),1.96(dq,J=12.3,6.1Hz,1H),1.83(dq,J=13.6,7.2Hz,1H),1.40(d,J=6.5Hz,3H).

[0037] Example 4: Synthesis of {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-3-methylphenyl}acetic acid (3) The synthesis route is as follows: [ka] Step 1: (4-bromo-3-methylphenyl)ethyl acetate (3-1) Compound D (1.00 g, 4.37 mmol) and 60 mL of ethanol were added to a 250 mL necked flask and stirred. The mixture was cooled to 0°C, and 1 mL of concentrated sulfuric acid was added dropwise. The synthesis and workup procedures were the same as for Compound 1-1, yielding Compound 3-1 (0.87 g, 77% yield). LC-MS (ESI) m / z: 257.0 [M+H] + .

[0038] Step 2: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-3-methylphenyl}ethyl acetate (3-2) In a 250 mL necked flask, free compound A (1.00 g, 4.16 mmol), compound 3-1 (1.28 g, 4.99 mmol), Pd(OAc)2 (50 mg, 0.20 mmol), X-Phos (100 mg, 0.20 mmol), Cs2CO3 (4.10 g, 12.48 mmol), and 50 mL of toluene were added. The synthesis and workup procedures were carried out according to those for compound 1-2, and compound 3-2 (0.73 g, 42% yield) was obtained. LCMS(ESI) m / z: 417.2 [M+H] + .

[0039] Step 3: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-3-methylphenyl}acetic acid (3) To a 100 mL single-necked flask was added Compound 3-2 (0.70 g, 1.68 mmol), sodium hydroxide (0.34 g, 8.40 mmol), 10 mL of purified water and 10 mL of ethanol. The synthesis and post-treatment procedures were the same as those for Compound 1, to afford Compound 3 (0.44 g, yield 67%). LCMS (ESI) m / z: 389.2 [M+H] + . 1 ¹H NMR (400 MHz, DMSO-d₆) δ 8.32 (d, J=8.0 Hz, 1H), 7.93 (dd, J=7.3, 2.1 Hz, 1H), 7.80 (d, J=8.1 Hz, 1H), 7.73 (d, J=7.1 Hz, 1H), 7.51 (qd, J=8.1, 7.3, 2.3 Hz, 3H), 6.97-6.86 (m, 2H), 6.71-6.64 (m, 1H), 4.71 (q, J=6.5 Hz, 1H), 3.38 (s, 2H), 3.18 (s, 1H), 3.13-3.06 (m, 2H), 3.02 (m, 1H), 2.92 (dd, J=9.2, 6.3 Hz, 1H), 2.11 (s, 3H), 1.99 (dq, J=12.6, 6.5 Hz, 1H), 1.86-1.73 (m, 1H), 1.41 (d, J=6.5 Hz, 3H).

[0040] Example 5: Synthesis of {4-[(3S)-3-{[(1R)-1-(naphthalen-1-yl)ethyl]amino}tetrahydro-1H-pyrrol-1-yl]-2-methylphenyl}acetic acid (4) The synthetic route is as follows. [Chemical formula] Step 1: Ethyl (4-bromo-2-methylphenyl)acetate (4-1) To a 250 mL single-necked flask was added Compound E (1.00 g, 4.37 mmol) and 60 mL of ethanol, the mixture was stirred, cooled to 0°C, and 1 mL of concentrated sulfuric acid was added dropwise. The synthesis and post-treatment procedures were the same as those for Compound 1-1, to afford Compound 4-1 (0.93 g, yield 83%). LCMS (ESI) m / z: 257.0 [M+H] + .

[0041] Step 2: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-methylphenyl}ethyl acetate (4-2) In a 250 mL necked flask, free compound A (1.00 g, 4.16 mmol), compound 4-1 (1.28 g, 4.99 mmol), Pd(OAc)2 (50 mg, 0.20 mmol), X-Phos (100 mg, 0.20 mmol), Cs2CO3 (4.10 g, 12.48 mmol), and 50 mL of toluene were added. The synthesis and workup procedures were carried out according to those for compound 1-2, yielding compound 4-2 (0.73 g, 42% yield). LC-MS (ESI) m / z: 417.2 [M+H] + .

[0042] Step 3: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-methylphenyl}acetic acid (4) Compound 4-2 (0.50 g, 1.20 mmol), sodium hydroxide (0.24 g, 6.00 mmol), 5 mL of purified water, and 5 mL of ethanol were added to a 100 mL necked flask. The synthesis and workup procedures were carried out according to those for Compound 1, and Compound 4 (0.32 g, 69% yield) was obtained. LC-MS (ESI) m / z: 389.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.30(d,J=8.0Hz,1H),7.92(dd,J=7.3,2.1Hz,1H),7.81(d,J=8.1Hz,1H),7.73(d,J=7.1Hz ,1H),7.53(qd,J=8.1,7.3,2.3Hz,3H),6.97-6.86(m,2H),6.71-6.64(m,1H),4.71(q,J=6. 5Hz,1H),3.38(s,2H),3.18(s,1H),3.13-3.06(m,2H),3.02(m,1H),2.91(dd,J=9.2,6.3Hz ,1H),2.10(s,3H),1.99(dq,J=12.6,6.5Hz,1H),1.86-1.72(m,1H),1.43(d,J=6.5Hz,3H).

[0043] Example 6: Synthesis of {2,6-difluoro-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}acetic acid (5) The synthesis route is as follows: [ka] Step 1: {2,6-difluoro-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}ethyl acetate (5-1) In a 250 mL necked flask, free compound A (861 mg, 3.58 mmol), compound F (1.00 g, 3.58 mmol), Pd(OAc)2 (80 mg, 0.36 mmol), X-Phos (171 mg, 0.36 mmol), Cs2CO3 (3.50 g, 10.74 mmol), and 50 mL of toluene were added. The synthesis and workup procedures were carried out according to those for compounds 1-2, yielding compound 5-1 (1.44 g, 74% yield). LC-MS (ESI) m / z: 439.2 [M+H] + .

[0044] Step 2: {2,6-difluoro-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}acetic acid (5) Compound 5-1 (1.44 g, 3.28 mmol), sodium hydroxide (0.66 g, 16.43 mmol), 5 mL of purified water, and 5 mL of ethanol were added to a 100 mL necked flask. The synthesis and workup procedures were carried out according to those for Compound 1, and Compound 5 (1.25 g, 93% yield) was obtained. LC-MS (ESI) m / z: 411.2 [M+H] + . 11H NMR (600 MHz, DMSO-d6) δ 8.30 (s, 1H), 7.94 (s, 1H), 7.85-7.78 (m, 1H), 7.73 (dd, J=10.9, 6.0 Hz, 1H), 7.57-7.47 (m, J=6.5, 5.5 Hz, 3H), 6.08 (dq, J=10.2, 5.2 Hz, 2H), 4.75 (dd, J=11.7, 6.0 Hz, 1H), 3.42 (q, J=5.5, 5.0 Hz, 2H), 3.37-3.23 (m, 3H), 3.11 (s, 1H), 2.99 (s, 1H), 2.05-1.98 (m, 1H), 1.94-1.88 (m, 1H), 1.42 (p, J=5.7 Hz, 3H).

[0045] Example 7: Synthesis of {4-[(3S)-3-{[(1R)-1-(naphthalen-1-yl)ethyl]amino}tetrahydro-1H-pyrrol-1-yl]-3-methoxyphenyl}acetic acid (6) The synthetic route is as follows. [Chemical Formula] Step 1: Methyl 4-bromo-3-methoxybenzoate (6-1) To a 100 mL single-neck flask, add free compound G (10.00 g, 0.046 mol), iodomethane (19.62 g, 0.14 mol), potassium carbonate (25.47 g, 0.18 mol) and 50 mL of DMF, allow the reaction to proceed overnight with stirring, add 500 mL of saturated brine and 100 mL of ethyl acetate and stir, let stand until the layers are clearly separated, perform phase separation, retain the organic phase, extract the aqueous phase twice with 50 mL of ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate under reduced pressure until no more solvent distills out from the filtrate, to obtain compound 6-1 (10.50 g, yield 93%). LCMS (ESI) m / z: 245.0 [M+H] + .

[0046] Step 2: (4-Bromo-3-methoxyphenyl)methanol (6-2) Compound 6-1 (10.50 g, 23.8 mmol) and 100 mL of anhydrous tetrahydrofuran were added to a 500 mL three-necked flask and stirred. The mixture was cooled to 0°C, and lithium aluminum hydride (1.95 g, 51.4 mmol) was added in several batches. The mixture was kept warm and reacted for 4.0 hours. 150 mL of 1N hydrochloric acid was slowly added and stirred. The mixture was allowed to stand until clear stratification occurred, and phase separation was performed. The organic phase was retained, and the aqueous phase was extracted twice with 50 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure until no more solvent was distilled from the filtrate. The residue was purified by column chromatography (200-300 mesh silica gel, petroleum ether:ethyl acetate = 95:5 → 80:20), concentrated under reduced pressure, and compound 6-2 (5.80 g, yield 62%) was obtained. LCMS(ESI) m / z: 217.0 [M+H] + .

[0047] Step 3: 1-Bromo-4-(bromomethyl)-2-methoxybenzene(6-3) Compound 6-2 (5.00 g, 23.00 mmol), triphenylphosphine (7.30 g, 27.60 mmol), carbon tetrabromide (8.40 g, 25.30 mmol), and 100 mL of dichloromethane were added to a 500 mL three-necked flask. The mixture was stirred overnight, and the solution was concentrated under reduced pressure until no more solvent distilled from the filtrate. The residue was purified by column chromatography (200-300 mesh silica gel, petroleum ether:ethyl acetate = 95:5 → 85:15), concentrated under reduced pressure, and compound 6-3 (5.80 g, 90% yield) was obtained. LCMS(ESI) m / z: 279.0 [M+H] + .

[0048] Step 4: (4-bromo-3-methoxyphenyl)acetonitrile (6-4) Compound 6-3 (5.00 g, 17.9 mmol), TBAF (5.60 g, 21.4 mmol), and 50 mL of acetonitrile were added to a 500 mL three-necked flask and stirred. The mixture was cooled to 0°C, and TMSCN (2.13 g, 21.4 mmol) was added in several portions. The mixture was stirred overnight, and the solution was concentrated under reduced pressure until no more solvent was distilled from the filtrate. The residue was purified by column chromatography (200-300 mesh silica gel, petroleum ether:ethyl acetate = 95:5 → 85:15), concentrated under reduced pressure, and compound 6-4 (3.60 g, yield 89%) was obtained. LCMS(ESI) m / z: 226.0 [M+H] + .

[0049] Step 5: (4-bromo-3-methoxyphenyl)ethyl acetate (6-5) Compound 6-4 (3.00 g, 13.27 mmol) and 50 mL of ethanol were added to a 500 mL three-necked flask and stirred. The mixture was cooled to 0°C, and 7.5 mL of concentrated sulfuric acid was added dropwise. The synthesis and workup procedures were the same as for compound 1-1, yielding compound 6-5 (3.20 g, 88% yield). LC-MS (ESI) m / z: 273.0 [M+H] + .

[0050] Step 6: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-3-methoxyphenyl}ethyl acetate (6-6) In a 100 mL necked flask, free compound A (1.00 g, 4.61 mmol), compound 6-5 (1.10 g, 4.99 mmol), Pd(OAc)2 (19 mg, 0.08 mmol), X-Phos (40 mg, 0.08 mmol), Cs2CO3 (4.00 g, 12.50 mmol), and 20 mL of toluene were added. The synthesis and workup procedures were carried out according to those for compound 1-2, and compound 6-6 (1.20 g, yield 67%) was obtained. LCMS(ESI) m / z: 433.2 [M+H] + .

[0051] Step 7: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-3-methoxyphenyl}acetic acid (6) Compound 6-6 (1.00 g, 2.31 mmol), sodium hydroxide (0.28 g, 6.93 mmol), 5 mL of purified water, and 5 mL of ethanol were added to a 100 mL necked flask. The synthesis and workup procedures were carried out according to those for Compound 1, and Compound 6 (0.31 g, 33% yield) was obtained. LC-MS (ESI) m / z: 405.2 [M+H] + . 1 H NMR(600MHz,DMSO-d6)δ 8.32(d,J=8.2Hz,1H),7.92(dd,J=7.7,1.8Hz,1H),7.79(d,J=8.2Hz,1H),7.72(dd,J=7.3,1.2Hz,1 H),7.55-7.46(m,3H),6.73(d,J=2.0Hz,1H),6.65(dd,J=8.1,1.9Hz,1H),6.48(d,J=8.1Hz,1H),4. 71(s,1H),3.64(s,3H),3.40(s,2H),3.22(dt,J=7.9,6.0Hz,2H),3.14(dt,J=9.4,6.8Hz,2H),3.01 (t,J=7.9Hz,1H),1.93(dt,J=13.2,6.6Hz,1H),1.77(dd,J=12.5,6.7Hz,1H),1.40(d,J=6.6Hz,3H).

[0052] Example 8: Synthesis of {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-methoxyphenyl}acetic acid (7) The synthesis route is as follows: [ka] Step 1: 4-Bromo-2-methoxyphenylethyl acetate (7-1) Compound H (10.00 g, 40.80 mmol) and 80 mL of ethanol were added to a 500 mL three-necked flask and stirred. The mixture was cooled to 0°C, and 1.5 mL of concentrated sulfuric acid was added dropwise. The synthesis and workup procedures were the same as for Compound 1-1, yielding Compound 7-1 (10.50 g, 94% yield). LC-MS (ESI) m / z: 245.0 [M+H] + .

[0053] Step 2: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-methoxyphenyl}ethyl acetate (7-2) In a 100 mL necked flask, free compound A (1.47 g, 6.11 mmol), compound 7-1 (2.00 g, 7.32 mmol), Pd(OAc)2 (70 mg, 0.31 mmol), X-Phos (150 mg, 0.31 mmol), Cs2CO3 (5.96 g, 12.50 mmol), and 20 mL of toluene were added. The synthesis and workup procedures were carried out according to those for compound 1-2, yielding compound 7-2 (1.60 g, 61% yield). LC-MS (ESI) m / z: 433.2 [M+H] + .

[0054] Step 3: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-methoxyphenyl}acetic acid (7) Compound 7-2 (1.60 g, 3.70 mmol), sodium hydroxide (0.59 g, 14.75 mmol), 5 mL of purified water, and 5 mL of ethanol were added to a 100 mL necked flask. The synthesis and workup procedures were carried out according to those for Compound 1, and Compound 7 (0.50 g, yield 33%) was obtained. LC-MS (ESI) m / z: 405.2 [M+H] + . 11H NMR (600MHz, DMSO-d6)δ 8.33(d,J=8.3Hz,1H),7.93(d,J=7.8Hz,1H),7.81(d,J=8.0Hz,1H),7.75(d,J =7.2Hz,1H),7.51(q,J=7.9,6.8Hz,3H),6.88(d,J=8.2Hz,1H),5.98(d,J=2.3H) z,1H),5.96(dd,J=8.4,2.2Hz,1H),4.76(s,1H),3.70(s,3H),3.32(s,4H),3. 12(dt,J=9.2,7.3Hz,1H),2.99(s,1H),2.04(s,1H),1.91(s,1H),1.42(s,3H).

[0055] Example 9: Synthesis of {2-ethoxy-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}acetic acid (8) The synthesis route is as follows: [ka] Step 1: 4-Bromo-2-ethoxybenzoate ethyl(8-1) Compound I (2.00 g, 7.72 mmol), potassium carbonate (3.20 g, 23.00 mmol), bromoethane (0.93 g, 8.40 mmol), and 50 mL of acetonitrile were added to a 250 mL three-necked flask, and the mixture was reacted at 60 °C with stirring for 24.0 hours. The mixture was cooled to room temperature and concentrated under reduced pressure until no more solvent distilled off. 50 mL of ethyl acetate and 50 mL of purified water were added, and the mixture was stirred. The mixture was allowed to stand until clear stratification occurred, and phase separation was performed. The organic phase was retained, and the aqueous phase was extracted once with 50 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure until constant weight was obtained to obtain compound 8-1 (2.02 g, yield 91%). LC-MS (ESI) m / z: 287.0 [M+H] + .

[0056] Step 2: {2-Ethoxy-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}ethyl acetate (8-2) In a 100 mL necked flask, free compound A (1.00 g, 4.16 mmol), compound 8-1 (2.00 g, 7.32 mmol), Pd(OAc)2 (70 mg, 0.31 mmol), X-Phos (150 mg, 0.31 mmol), Cs2CO3 (4.51 g, 13.90 mmol), and 20 mL of toluene were added. The synthesis and workup procedures were carried out according to those for compound 1-2, and compound 8-2 (1.60 g, yield 86%) was obtained. LCMS(ESI) m / z: 447.3 [M+H] + .

[0057] Step 3: {2-Ethoxy-4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]phenyl}acetic acid (8) Compound 8-2 (1.60 g, 3.53 mmol), sodium hydroxide (0.60 g, 15.00 mmol), 10 mL of purified water, and 10 mL of ethanol were added to a 100 mL necked flask. The synthesis and workup procedures were carried out according to those for Compound 1, and Compound 8 (0.52 g, 35% yield) was obtained. LC-MS (ESI) m / z: 419.2 [M+H] + . 1 H NMR(600MHz,DMSO-d6)δ 11.70(s,1H),10.23(s,1H),9.78(s,1H),8.39(d,J=8.5Hz,1H),8.12(s,1H),8.02(t, J=8.9Hz,2H),7.64(d,J=7.5Hz,2H),7.60(t,J=7.5Hz,1H),6.93(d,J=8.0Hz,1H),6.02 (d,J=9.1Hz,2H),5.42(s,1H),3.96(q,J=7.0Hz,2H),3.82(s,1H),3.40(t,J=7.1Hz,3H ),3.15(q,J=8.1Hz,1H),2.34(s,1H),2.26(s,1H),1.76(s,3H),1.29(t,J=7.0Hz,3H).

[0058] Example 10: Synthesis of {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-(propa-2-yloxy)phenyl}acetic acid (9) The synthesis route is as follows: [ka] Step 1: [4-bromo-2-(propa-2-yloxy)phenyl]ethyl acetate (9-1) Compound I (2.00 g, 7.72 mmol), potassium carbonate (3.20 g, 23.15 mmol), isopropyl bromide (1.04 g, 8.49 mmol), and 50 mL of acetonitrile were added to a 250 mL three-necked flask. The synthesis and workup procedures were carried out according to those for Compound 8-1, yielding Compound 9-1 (1.95 g, 84% yield). LC-MS (ESI) m / z: 301.0 [M+H] + .

[0059] Step 2: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-(propa-2-yloxy)phenyl}ethyl acetate (9-2) In a 100 mL necked flask, free compound A (0.80 g, 3.32 mmol), compound 9-1 (1.20 g, 3.32 mmol), Pd(OAc)2 (40 mg, 0.16 mmol), X-Phos (80 mg, 0.16 mmol), Cs2CO3 (3.25 g, 9.96 mmol), and 20 mL of toluene were added. The synthesis and workup procedures were carried out according to those for compound 1-2, yielding compound 9-2 (0.80 g, 52% yield). LCMS(ESI) m / z: 461.3 [M+H] + .

[0060] Step 3: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-(propa-2-yloxy)phenyl}acetic acid (9) Compound 9-2 (0.80 g, 1.70 mmol), sodium hydroxide (0.20 g, 5.20 mmol), 10 mL of purified water, and 10 mL of ethanol were added to a 100 mL necked flask. The synthesis and workup procedures were carried out according to those for Compound 1, and Compound 9 (0.50 g, 68% yield) was obtained. LC-MS (ESI) m / z: 433.2 [M+H] + . 1 H NMR(600MHz,DMSO-d6)δ 8.32(d,J=8.0Hz,1H),7.92(dd,J=7.2,2.3Hz,1H),7.79(d,J=8.1Hz,1H),7.74(d,J=7.2Hz,1H),7.51(qd,J= 7.2,5.1Hz,3H),6.87(d,J=8.7Hz,1H),5.94(dq,J=4.4,2.3Hz,2H),4.73(d,J=6.9Hz,1H),4.50-4.42(m,1H), 3.29(d,J=4.1Hz,3H),3.24(t,J=6.3Hz,1H),3.20(dd,J=9.0,6.6Hz,1H),3.09(dt,J=9.1,7.2Hz,1H),2.92(d d,J=9.1,5.5Hz,1H),2.02(dd,J=12.2,6.3Hz,1H),1.87(s,1H),1.40(d,J=6.6Hz,3H),1.21(d,J=6.0Hz,6H).

[0061] Example 11: Synthesis of {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-(propyloxy)phenyl}acetic acid (10) The synthesis route is as follows: [ka] Step 1: [4-bromo-2-(propyloxy)phenyl]ethyl acetate (10-1) Compound I (2.00 g, 7.72 mmol), potassium carbonate (3.20 g, 23.15 mmol), n-propyl bromide (1.04 g, 8.49 mmol), and 50 mL of acetonitrile were added to a 250 mL three-necked flask. The synthesis and workup procedures were carried out according to those for Compound 8-1, yielding Compound 10-1 (1.57 g, 68% yield). LC-MS (ESI) m / z: 301.0 [M+H] + .

[0062] Step 2: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-(propyloxy)phenyl}ethyl acetate (10-2) In a 100 mL necked flask, free compound A (1.04 g, 4.31 mmol), compound 10-1 (1.57 g, 5.20 mmol), Pd(OAc)2 (50 mg, 0.22 mmol), X-Phos (100 mg, 0.22 mmol), Cs2CO3 (4.25 g, 13.04 mmol), and 20 mL of toluene were added. The synthesis and workup procedures were carried out according to those for compound 1-2, and compound 10-2 (0.45 g, yield 23%) was obtained. LCMS(ESI) m / z: 461.3 [M+H] + .

[0063] Step 3: {4-[(3S)-3-{[(1R)-1-(naphthalene-1-yl)ethyl]amino}tetrahydro-1H-pyrrole-1-yl]-2-(propyloxy)phenyl}acetic acid (10) Compound 10-2 (0.45 g, 0.98 mmol), sodium hydroxide (0.12 g, 3.00 mmol), 10 mL of purified water, and 10 mL of ethanol were added to a 100 mL necked flask. The synthesis and workup procedures were carried out according to those for Compound 1, and Compound 10 (0.38 g, 90% yield) was obtained. LC-MS (ESI) m / z: 433.2 [M+H] + . 11H NMR (600MHz, DMSO-d6)δ 8.33(d,J=8.3Hz,1H),7.94(d,J=7.8Hz,1H),7.82(s,1H),7.76(s,1H),7.52(dt ,J=15.4,8.8Hz,3H),6.88(d,J=8.3Hz,1H),5.95(s,2H),4.78(s,1H),3.84(t,J =6.3Hz,2H),3.32(s,4H),3.27(s,1H),3.11(q,J=7.8Hz,1H),2.99(s,1H),2.06 (s,1H),1.94(s,1H),1.68(h,J=6.7Hz,2H),1.44(s,3H),0.97(t,J=7.4Hz,3H).

[0064] Experimental Example 1: In vitro experiment on the allosteric activation effect of CaSR CaSR is a member of the G protein-coupled receptor (GPCR) C family. Extracellular Ca 2+ Alternatively, when a compound activates CaSR on a cell, the intracellular Ca 2+ The concentration will increase. Therefore, using a cell line in which hCaSR-CHO has been stably introduced, the intracellular Ca 2+ Using concentration as a measurement indicator, intracellular Ca 2+ The allosteric activation effect of compounds on CaSR is evaluated by measuring changes in concentration.

[0065] 1. Experimental Steps (1) Prepare the cells before seeding. 12 hours before seeding, 384-well cell culture plates were coated with 0.1 mg / mL of polylysine.

[0066] (2) Seed the cells. Resuspend the digested hCaSR-CHO cells in complete medium and count them with a cell counter to obtain a cell density of 5 × 10⁻⁶. 5 The cell suspension was adjusted to 1 cell / mL, with 25 μL of cell suspension inoculated per well. After inoculation, the cells were incubated in a 37°C, 5% CO2 incubator for 18 hours.

[0067] (3) Prepare the test compound solution. The test compound was serially diluted to the specified concentrations (10 μM, 2 μM, 400 nM, 80 nM, 16 nM, 3.2 nM, and 0.64 nM) and added to a 384-well loading plate in preparation for use. At this time, since the test cell culture plate already contained 25 μL of Fluo-4 NW measurement reagent, the administration system in the instrument was set to 20 μL. Therefore, the compound concentration in the loading plate at this time was 2.25 times the actual measurement concentration, that is, the compound concentration in the loading well of the 10 μM compound was 22.5 μM, and so on for the others.

[0068] (4) Prepare the measurement reagent. Following the instructions in the Fluo-4 NW Calcium Assay Kits (Thermo, F36206) manual, 1 mL of assay buffer was added to Component B to prepare a 250 mM probenecid solution. Next, 100 μL was taken from the probenecid solution and added to 10 mL of assay buffer. After thoroughly mixing until homogeneous, it was added to Component A to obtain a 1 × dye loading solution.

[0069] (5) Add the fluorescent dye. Discard the complete medium, add 25 μL of 1× dye loading solution to a 384-well plate using a multidrop automated dispenser, let it stand in the dark, incubate at 37°C for 30 minutes, let it stand at room temperature for another 30 minutes, and then transfer to a Fliper Tetra (Molecular Devices).

[0070] (6) Read the original experimental data. Add 20 μL of the test compound solution, set the excitation wavelength range to 470-495 nm, measure the emitted light in the range of 515-575 nm, read the quality inspection plate of the device to confirm it is correct, and start the measurement. The continuous measurement time was 660 seconds, and after reading the data, export the data.

[0071] (7) Data processing. The change in fluorescence intensity was obtained by subtracting the minimum fluorescence value (MIN, average over 14-21 seconds) from the maximum fluorescence value (MAX, average over 40-80 seconds) after administration of a predetermined drug concentration. This was used to represent the changes in intracellular calcium signaling. Using GraphPad Prism 8.0, the drug administration concentration was plotted on the x-axis and the change in fluorescence intensity on the y-axis, and the EC of each compound was plotted. 50 The value was calculated.

[0072] 2. Experimental Results The in vitro pharmacodynamic results for some of the compounds of the present invention are shown in Table 1. Table 1: Cell pharmacodynamic experimental data of compounds [Table 1]

[0073] Experiment Example 2: In vivo experiment on inhibiting PTH concentration in the blood of model rats A male SD rat hyperparathyroidism model will be constructed by inducing it through 5 / 6 nephrectomy and a special diet. Parathyroid hormone (PTH) in the blood will be used as a measurement indicator, and the change in PTH concentration in rat plasma after compound administration will be measured using the ELISA method to evaluate the in vivo activity of the compound.

[0074] 1. Experimental Steps (1) Construct a model. Use SPF-treated male SD rats aged 7-8 weeks. They were fed a normal diet for one week until they adapted. Two-thirds of the left kidney was removed, and the rats were fed a normal diet for one week to allow it to recover. The right kidney was removed, and the rats were fed a normal diet for one week to allow it to recover. The rats were fed a special diet (calcium content 0.5%, total phosphorus content 1.2%) for two weeks.

[0075] (2) Measurement and grouping were performed. Approximately 300 μL of blood was collected from the tail vein, placed in a blood collection tube containing a coagulation accelerator, allowed to stand at room temperature for 30 minutes, and then centrifuged at 12000 rpm for 3 minutes to obtain a serum sample. The concentration of intact PTH (1-84) in the serum was measured using the MicroVue Intact PTH EIA-96 Test (Quidel, catalog number 60-2500). Rats were grouped based on their PTH concentration levels, and the average PTH concentration of rats in each group was approximately the same.

[0076] (3) Administration and activity measurement were performed. A fixed dose of the compound was administered intragastricly as a single dose, and blood samples were collected before and after administration. Serum was obtained by processing it using the method described above, and the PTH content was measured by ELISA. This method demonstrated that the compound has the effect of reducing blood PTH levels in model rats.

[0077] 2. Experimental Results The effect of some of the compounds of the present invention on reducing blood PTH in model rats is shown in Table 2. Table 2: In vivo pharmacodynamic experimental data of compounds [Table 2] This refers to the efficiency of reducing PTH levels one hour after administration compared to the PTH concentration at 0 hours.

[0078] Experiment Example 3: Stability experiment in rat liver microsomes Rat liver microsomes at a constant concentration, testosterone (positive control), tolbutamide (internal standard), the test compound, and PBS (pH 7.4) were incubated at 37°C. Each sample was then quenched with methanol at 0, 5, 10, 20, 30, and 60 minutes. The samples were pre-treated and measured using LC-MS. The data was processed (the peak area of ​​the test compound / the peak area of ​​the internal standard was plotted as the y-coordinate, and time as the x-coordinate). 1 / 2 The following was calculated. The measurement results for some of the compounds of the present invention are shown in Table 3. Table 3: Experimental data on compound stability in rat liver microsomes [Table 3] Liver microsome stability experiments showed little influence from liver microsome activity, and the maximum incubation time for in vitro experiments was 60 minutes. 1 / 2 Since the reaction time is >60 minutes, it is presumed that the compound has high metabolic stability in the body.

[0079] Experimental Example 4: Pharmacokinetic Experiment in SD Rat 1. Experimental Steps (1)Animal species We used normal 7-8 week old male SD rats, with 3-5 rats per group.

[0080] (2) Administration method The patient was fasted for at least 12 hours prior to administration, and the drug was administered as a single intragastric dose.

[0081] (3) Time of blood collection Blood samples were collected from the tail vein before administration and at 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours after administration, with 100 μL of blood sample collected at each time point.

[0082] (4) Processing and saving of samples After collecting blood samples, they were transferred to 1.5 mL EP tubes, with 50 μL per tube, and each sample consisted of two tubes. Centrifugation was completed within 2 hours. Whole blood samples were stored in an ice bath before centrifugation. The centrifugation conditions were 4000 rpm, 2-8°C, and 10 minutes. After aspirating the supernatant, if not measured immediately, it was stored at -80°C or below.

[0083] (5) Measurement a) The chromatography column was an Infinitylab poroshell 120 SB C18 2.1×100 mm, 2.7 μm. The column temperature was 30°C. The flow rate was 0.3 mL / min. The run time was 9.5 minutes. The post-run time was 2 minutes. The injection volume was 2 μL. The mobile phase was methanol-0.1% formic acid. Gradient elution was performed as shown in the table below. [Table 4]

[0084] b) Parameters of mass spectrometry [Table 5]

[0085] c) Preparation of stock solution and working solution samples All prepared stock solutions should be stored in a refrigerator at -80°C, and the working solution should be stored in a refrigerator at 4°C. Evocalcet stock solution (0.2 mg / mL) was obtained by accurately weighing 10 mg of the substance, placing it in a 50 mL volumetric flask, dissolving it in methanol, bringing it to the designated mark, and shaking it by hand until homogeneous (the preparation of the compound stock solution was the same as for evocalcet).

[0086] Standard solutions were prepared. Accurately weighed out the stock solutions of evocalcet, compound 2, and compound 3, diluted them with 50% methanol, and standard solutions were prepared with concentrations of 80 ng / mL, 200 ng / mL, 1000 ng / mL, 5000 ng / mL, 10000 ng / mL, 20000 ng / mL, and 40000 ng / mL.

[0087] Prepare a solution of clenbuterol hydrochloride, which is the internal standard substance. Accurately weigh 10 mg of clenbuterol hydrochloride, place it in a 10 mL volumetric flask, dissolve it in methanol, and bring it to the designated mark. Shake by hand until homogeneous to obtain the stock solution of clenbuterol hydrochloride (1.0 mg / mL). Accurately measure an appropriate amount of the stock solution and dilute it with methanol to a 2000 ng / mL internal standard substance working solution.

[0088] d) Sample processing procedure Standard curve samples were processed. 90 μL of blank matrix was obtained, and 10 μL of standard series solution and 50 μL of internal standard solution were added to each, and the mixture was vortexed for 30 seconds to ensure homogeneity. 350 μL of methanol was added to precipitate the protein solution, and the mixture was vortexed again. The samples were centrifuged at 12000 rpm for 10 minutes, 200 μL of supernatant was taken, 600 μL of water was added and mixed homogeneously, and the supernatant was obtained and injected for analysis.

[0089] The blood sample was processed. A 50 μL plasma sample was taken, 25 μL of internal standard solution was added, and the mixture was vortexed for 30 seconds to ensure homogeneity. 175 μL of methanol was added to precipitate the protein solution, and the mixture was vortexed again. The sample was centrifuged at 12000 rpm for 10 minutes. 100 μL of the supernatant was taken, 300 μL of water was added, and the mixture was homogeneously mixed. The supernatant was then obtained, injected, and analyzed.

[0090] 2. Experimental Results The results are shown in Table 4. Table 4 [Table 6]

Claims

1. A compound having the structure shown in formula (I), or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof. 【Chemistry 1】 (where R 1 , R 2 , R 3 , R 4 , R 5 each independently represent a hydrogen atom; C 2~6 carboxy group; a C substituted by a substituent selected from halogen, cyano group, nitro group, oxygen, C 1~6 carboxy group, amine group, C 3~6 cycloalkyl group, aryl C 1~6 alkoxy group, hydroxy group, C 1~6 alkoxy group, halo C 1~6 alkyl group and halo C 1~6 alkoxy group 1~7 alkoxy group; halogen; C 1~6 alkyl group; selected from halo C 1~6 alkyl group, However, 1) R 1 , R 2 , R 3 , R 4 , R 5 1) It is not possible for both to be H at the same time, and 2) the substituent is C 2~6 If it is a carboxyl group, the substitution site is R 2 ~R 4 And R 1 ~R 5 At least two of them are not H.

2. R 1 , R 5 H, halogen, C 1~6 Alkyl alkyl group, C 1~6 A compound according to claim 1, selected from alkoxy groups, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

3. R 2 ~R 4 At least one of them is either an unsubstituted or substituted C 2~6 It is a carboxyl group, preferably a carboxymethyl group, and R 1 ~R 5 At least two of them are not H, preferably R 2 ~R 4 At least one of them is an unsubstituted or substituted carboxymethyl group, and R 1 ~R 5 A compound according to claim 1 or 2, wherein at least two of the atoms are not H, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

4. R 1 , R 2 , R 4 , R 5 These are H, halogen, and C, respectively, independently. 1~6 Alkyl alkyl group, C 1~6 Selected from alkoxy groups, where C 1~6 The alkoxy group is a hydroxyl group, C 1~6 It may be substituted with a substituent selected from the alkoxy group, and R 1 , R 2 , R 4 , R 5 It is not possible for both to be H at the same time, R 3 is C 2~6 It is a carboxyl group, Preferably, R 1 , R 2 , R 4 , R 5 These are H, halogen, and C, respectively, independently. 1~6 Alkyl alkyl group, C 1~6 Selected from alkoxy groups, where C 1~6 The alkoxy group is a hydroxyl group, C 1~6 It may be substituted with a substituent selected from the alkoxy group, and R 1 , R 2 , R 4 , R 5 It is not possible for both to be H at the same time, R 3 The compound according to any one of claims 1 to 3, wherein is a carboxymethyl group, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

5. The compound of formula (I) is selected from the following, the compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof. 【Chemistry 2】

6. The process includes the step of reacting the compound of formula A with the compound of formula (II) to produce the compound of formula (I), 【Transformation 3】 Here, X represents a leaving group, and can be a halogen, a hydroxyl group, or a lower alkylsulfonyloxy group (for example, C 1~6 A method for producing a compound of formula (I) according to any one of claims 1 to 5, wherein the group is selected from alkylsulfonyloxy groups, sulfonyloxy groups, and the like, and preferably Br, Cl, or trifluoromethanesulfonyloxy groups.

7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.

8. Use of a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, or the pharmaceutical composition according to claim 6, in the manufacture of a drug for preventing and / or treating a disease related to CaSR.

9. The aforementioned diseases include primary hyperparathyroidism, secondary hyperparathyroidism, tertiary hyperparathyroidism, chronic renal failure, chronic kidney disease, parathyroid adenoma, parathyroid hyperplasia, parathyroid cancer, vascular calcification and valve calcification, calcium homeostasis, phosphorus homeostasis, bone-related diseases or complications caused by hyperparathyroidism, chronic kidney disease or parathyroid cancer, post-renal osteopenia, cystic fibrous osteitis, asthenic osteodystrophy, renal osteodystrophy, cardiovascular complications caused by hyperparathyroidism or chronic kidney disease, and Ca 2+ The use according to claim 8, selected from a certain number of malignant tumors in which the ratio is abnormally high.